Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer

被引：9
作者：
Shah, Hina [1 ,2 ,3 ]
Ravi, Praful [3 ,4 ]
Sonpavde, Guru [3 ,4 ]
Jacene, Heather [1 ,2 ,3 ]
机构：
[1] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2022年 / 22卷 / 11期
关键词：
Lutetium-177; prostate cancer; PSMA-617; Lu-177-vipivotide tetraxetan; MITOXANTRONE PLUS PREDNISONE; RADIOLIGAND THERAPY; ABIRATERONE ACETATE; DOUBLE-BLIND; OPEN-LABEL; RADIONUCLIDE THERAPY; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; PSMA INHIBITOR; PHASE-III;
D O I：
10.1080/14737140.2022.2139679
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Introduction Lu-177-vipivotide tetraxetan is a radiopharmaceutical that selectively targets prostate-specific membrane antigen (PSMA) and delivers beta-radiations to kill prostate cancer cells. Areas covered Extensive experience outside the United States as well as randomized phase II and phase III data demonstrate that Lu-177-vipivotide tetraxetan is a safe, generally well tolerated, and effective therapy for men with mCRPC. Lu-177-vipivotide tetraxetan was approved by the FDA in March 2022 for the treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition and taxane-based chemotherapy based on the results of the VISION trial. Expert opinion This review discusses the development and studies leading to the approval of Lu-177-vipivotide tetraxetan. In all, Lu-177-vipivotide tetraxetan is an exciting new tool in the arsenal for men with mCRPC after novel androgen pathway inhibitors and at least one taxane chemotherapy. Optimal selection of patients, sequencing of Lu-177-vipivotide tetraxetan with the other agents available to treat mCRPC, and the use of dosimetry are current areas of interest with great potential and opportunities for further individual patient optimization using the tools of theranostics.
引用
收藏
页码：1163 / 1175
页数：13
相关论文
共 87 条
[1]   Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study [J].
Abida, Wassim ;
Campbell, David ;
Patnaik, Akash ;
Shapiro, Jeremy D. ;
Sautois, Brieuc ;
Vogelzang, Nicholas J. ;
Voog, Eric G. ;
Bryce, Alan H. ;
McDermott, Ray ;
Ricci, Francesco ;
Rowe, Julie ;
Zhang, Jingsong ;
Piulats, Josep Maria ;
Fizazi, Karim ;
Merseburger, Axel S. ;
Higano, Celestia S. ;
Krieger, Laurence E. ;
Ryan, Charles J. ;
Feng, Felix Y. ;
Simmons, Andrew D. ;
Loehr, Andrea ;
Despain, Darrin ;
Dowson, Melanie ;
Green, Foad ;
Watkins, Simon P. ;
Golsorkhi, Tony ;
Chowdhury, Simon .
CLINICAL CANCER RESEARCH, 2020, 26 (11) :2487-2496
[2]   The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].
Afshar-Oromieh, Ali ;
Hetzheim, Henrik ;
Kratochwil, Clemens ;
Benesova, Martina ;
Eder, Matthias ;
Neels, Oliver C. ;
Eisenhut, Michael ;
Kuebler, Wolfgang ;
Holland-Letz, Tim ;
Giesel, Frederik L. ;
Mier, Walter ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705
[3]   Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study [J].
Ahmadzadehfar, Hojjat ;
Rahbar, Kambiz ;
Kuerpig, Stefan ;
Boegemann, Martin ;
Claesener, Michael ;
Eppard, Elisabeth ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Schaefers, Michael ;
Essler, Markus .
EJNMMI RESEARCH, 2015, 5 :1-8
[4]   Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223 [J].
Al-Ezzi, Esmail M. ;
Alqaisi, Husam A. ;
Iafolla, Marco A. J. ;
Wang, Lisa ;
Sridhar, Srikala S. ;
Sacher, Adrian G. ;
Fallah-Rad, Nazanin ;
Jiang, Di M. ;
Watson, Geoffrey A. ;
Catton, Charles N. ;
Warde, Padraig R. ;
Hamilton, Rob J. ;
Fleshner, Neil E. ;
Zlotta, Alexandre R. ;
Hansen, Aaron R. .
CANCER MEDICINE, 2021, 10 (17) :5775-5782
[5]  
[Anonymous], 2022, NCCN GUIDELINES VERS
[6]  
[Anonymous], 2022, LUTETIUM LU 177 VIPI
[7]   Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications [J].
Banerjee, Sharmila ;
Pillai, M. R. A. ;
Knapp, F. F. .
CHEMICAL REVIEWS, 2015, 115 (08) :2934-2974
[8]   Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride [J].
Baumgarten, Justus ;
Groener, Daniel ;
Nguyen Ngoc, Christina ;
Mader, Nicolai ;
Chaurasia, Maximilian ;
Davis, Karen ;
Wichert, Jennifer ;
Chun, Felix K. H. ;
Tselis, Nikolaos ;
Happel, Christian ;
Gruenwald, Frank ;
Sabet, Amir .
CANCERS, 2022, 14 (03)
[9]  
Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
[10]   Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].
Benesova, Martina ;
Schaefer, Martin ;
Bauder-Wuest, Ulrike ;
Afshar-Oromieh, Ali ;
Kratochwil, Clemens ;
Mier, Walter ;
Haberkorn, Uwe ;
Kopka, Klaus ;
Eder, Matthias .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920
123456789